The Cellular Immunotherapy Revolution: Arming the Immune System for Precision Therapy

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · see citing works

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · see citing works

Cancer immunotherapy using checkpoint blockade

Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791 · see citing works

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia

Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735 · see citing works

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413 · see citing works

Enhancement of Antitumor Immunity by CTLA-4 Blockade

Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955 · see citing works

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,373 · see citing works

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237 · see citing works

Car t cell immunotherapy for human cancer

June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207 · see citing works

Molecular mechanisms of T cell co-stimulation and co-inhibition

Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114 · see citing works

An immunogenic personal neoantigen vaccine for patients with melanoma

Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936 · see citing works

Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823 · see citing works

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488 · see citing works

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,484 · see citing works

Chimeric antigen receptor T-cell therapy—assessment and management of toxicities

Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438 · see citing works

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

Kalos, M. D., Levine, B. L., Porter, D. L., Katz, S. I., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,389 · see citing works

Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma

Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198812223192527 · Cited by 2,389 · see citing works

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

O’Rourke, D. M., Nasrallah, M. P., Desai, A. S., Melenhorst, J. J., Mansfield, K. G., Morrissette, J. J. D., Martinez‐Lage, M., Brem, S. S., Maloney, E., Shen, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa0984 · Cited by 1,812 · see citing works

Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer

Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y., Dudley, M. E., Wunderlich, J. R., Somerville, R. P. T., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,710 · see citing works

T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition

Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689 · see citing works

Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

Robbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C.-H., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2537 · Cited by 1,635 · see citing works

Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy

Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512 · see citing works

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

Keskin, D. B., Anandappa, A. J., Sun, J., Tirosh, I., Mathewson, N. D., Li, S., Oliveira, G., Giobbie-Hurder, A., Felt, K., Gjini, E., et al. (2019) · Nature · doi:10.1038/s41586-018-0792-9 · Cited by 1,432 · see citing works

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

Johnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C.-H., Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211714 · Cited by 1,421 · see citing works

Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells

Norelli, M., Camisa, B., Barbiera, G., Falcone, L., Purevdorj, A., Genua, M., Sanvito, F., Ponzoni, M., Doglioni, C., Cristofori, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0036-4 · Cited by 1,406 · see citing works

Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells

Gust, J., Hay, K. A., Hanafi, L.-A., Li, D., Myerson, D., Gonzalez-Cuyar, L. F., Yeung, C., Liles, W. C., Wurfel, M., Lopez, J. A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0698 · Cited by 1,400 · see citing works

A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells

Carreno, B. M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A. A., Ly, A., Lie, W.-R., Hildebrand, W. H., Mardis, E. R., et al. (2015) · Science · doi:10.1126/science.aaa3828 · Cited by 1,285 · see citing works

CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade

Giavridis, T., van der Stegen, S. J. C., Eyquem, J., Hamieh, M., Piersigilli, A., & Sadelain, M. (2018) · Nature Medicine · doi:10.1038/s41591-018-0041-7 · Cited by 1,272 · see citing works

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy

Sotillo, E., Barrett, D. M., Black, K. L., Bagashev, A., Oldridge, D. A., Wu, G. S., Sussman, R. T., Lanauze, C. B., Ruella, M., Gazzara, M. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1020 · Cited by 1,251 · see citing works

Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells

Kawalekar, O. U., O’Connor, R. S., Fraietta, J. A., Guo, L., McGettigan, S. E., Posey, A. D., Patel, P. R., Guedan, S., Scholler, J., Keith, B., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.021 · Cited by 1,234 · see citing works

Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy

Morgan, R. A., Chinnasamy, N., Abate‐Daga, D., Gros, A., Robbins, P. F., Zheng, Z., Dudley, M. E., Feldman, S. A., Yang, J. C., Sherry, R. M., et al. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182829903 · Cited by 1,155 · see citing works

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., et al. (2018) · Science · doi:10.1126/science.aao4572 · Cited by 1,142 · see citing works

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

Gardner, R., Finney, O. C., Annesley, C., Brakke, H., Summers, C. N., Leger, K. J., Bleakley, M., Brown, C., Mgebroff, S., Kelly‐Spratt, K. S., et al. (2017) · Blood · doi:10.1182/blood-2017-02-769208 · Cited by 1,124 · see citing works

Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity

Hirano, F., Kaneko, K., Tamura, H., Dong, H., Wang, S., Ichikawa, M., Rietz, C., Flies, D. B., Lau, J. S., Zhu, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.1089.65.3 · Cited by 1,018 · see citing works

Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent

Kamphorst, A. O., Wieland, A., Nasti, T., Yang, S., Zhang, R., Barber, D. L., Konieczny, B. T., Daugherty, C. Z., Koenig, L., Yu, K., et al. (2017) · Science · doi:10.1126/science.aaf0683 · Cited by 1,015 · see citing works

Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits

Roybal, K. T., Rupp, L. J., Morsut, L., Walker, W. J., McNally, K. A., Park, J. S., & Lim, W. A. (2016) · Cell · doi:10.1016/j.cell.2016.01.011 · Cited by 1,010 · see citing works

Resistance to checkpoint blockade therapy through inactivation of antigen presentation

Sade-Feldman, M., Jiao, Y. J., Chen, J. H., Rooney, M. S., Barzily-Rokni, M., Eliane, J.-P., Bjorgaard, S. L., Hammond, M. R., Vitzthum, H., Blackmon, S. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01062-w · Cited by 1,005 · see citing works

Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors

Morsut, L., Roybal, K. T., Xiong, X., Gordley, R. M., Coyle, S. M., Thomson, M., & Lim, W. A. (2016) · Cell · doi:10.1016/j.cell.2016.01.012 · Cited by 1,002 · see citing works

Naive CD4+ T Cell Frequency Varies for Different Epitopes and Predicts Repertoire Diversity and Response Magnitude

Moon, J. J., Chu, H., Pepper, M., McSorley, S. J., Jameson, S. C., Kedl, R. M., & Jenkins, M. K. (2007) · Immunity · doi:10.1016/j.immuni.2007.07.007 · Cited by 977 · see citing works

Treatment of Metastatic Renal Cell Carcinoma With Autologous T-Lymphocytes Genetically Retargeted Against Carbonic Anhydrase IX: First Clinical Experience

Lamers, C. H. J., Sleijfer, S., Vulto, A. G., Kruit, W. H. J., Kliffen, M., Debets, R., Gratama, J. W., Stoter, G., & Oosterwijk, E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9964 · Cited by 915 · see citing works

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

Fraietta, J. A., Nobles, C. L., Sammons, M. A., Lundh, S., Carty, S. A., Reich, T. J., Cogdill, A. P., Morrissette, J. J. D., DeNizio, J. E., Reddy, S., et al. (2018) · Nature · doi:10.1038/s41586-018-0178-z · Cited by 862 · see citing works

NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma

Rapoport, A. P., Stadtmauer, E. A., Binder-Scholl, G. K., Goloubeva, O. G., Vogl, D. T., Lacey, S. F., Badros, A. Z., Garfall, A. L., Weiss, B. M., Finklestein, J. M., et al. (2015) · Nature Medicine · doi:10.1038/nm.3910 · Cited by 857 · see citing works

Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells

Zhao, Z., Condomines, M., van der Stegen, S. J. C., Perna, F., Kloss, C. C., Gunset, G., Plotkin, J., & Sadelain, M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.004 · Cited by 843 · see citing works

Reprogramming human T cell function and specificity with non-viral genome targeting

Roth, T. L., Puig-Saus, C., Yu, R., Shifrut, E., Carnevale, J., Li, P. J., Hiatt, J., Saco, J., Krystofinski, P., Li, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0326-5 · Cited by 839 · see citing works

A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

Robbins, P. F., Kassim, S. H., Tran, T. L. N., Crystal, J. S., Morgan, R. A., Feldman, S. A., Yang, J. C., Dudley, M. E., Wunderlich, J. R., Sherry, R. M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2708 · Cited by 807 · see citing works

IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor

Adachi, K., Kano, Y., Nagai, T., Okuyama, N., Sakoda, Y., & Tamada, K. (2018) · Nature Biotechnology · doi:10.1038/nbt.4086 · Cited by 796 · see citing works

Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer

Zacharakis, N., Chinnasamy, H., Black, M. A., Xu, H., Lu, Y., Zheng, Z., Pasetto, A., Langhan, M. M., Shelton, T. E., Prickett, T. D., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0040-8 · Cited by 770 · see citing works

CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells

Rupp, L. J., Schumann, K., Roybal, K. T., Gate, R. E., Ye, C. J., Lim, W. A., & Marson, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-00462-8 · Cited by 757 · see citing works

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy

Gardner, R., Wu, D., Cherian, S., Fang, M., Hanafi, L., Finney, O. C., Smithers, H. M., Jensen, M. C., Riddell, S. R., Maloney, D. G., et al. (2016) · Blood · doi:10.1182/blood-2015-08-665547 · Cited by 751 · see citing works

PD-1– and CTLA-4–Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses

Fedorov, V. D., Themeli, M., & Sadelain, M. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006597 · Cited by 737 · see citing works

Generation of knock-in primary human T cells using Cas9 ribonucleoproteins

Schumann, K., Lin, S., Boyer, E., Simeonov, D. R., Subramaniam, M., Gate, R. E., Haliburton, G. E., Ye, C. J., Bluestone, J. A., Doudna, J. A., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1512503112 · Cited by 702 · see citing works

Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism

Johnson, M. O., Wolf, M. M., Madden, M. Z., Andrejeva, G., Sugiura, A., Contreras, D. C., Maseda, D., Liberti, M. V., Paz, K. G., Kishton, R. J., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.001 · Cited by 702 · see citing works

Remote control of therapeutic T cells through a small molecule–gated chimeric receptor

Wu, C.-Y., Roybal, K. T., Puchner, E. M., Onuffer, J., & Lim, W. A. (2015) · Science · doi:10.1126/science.aab4077 · Cited by 692 · see citing works

Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells

Cameron, B., Gerry, A. B., Dukes, J. D., Harper, J. V., Kannan, V., Bianchi, F., Grand, F., Brewer, J. E., Gupta, M., Plesa, G., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006034 · Cited by 685 · see citing works

Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses

Cho, J. H., Collins, J. J., & Wong, W. W. (2018) · Cell · doi:10.1016/j.cell.2018.03.038 · Cited by 685 · see citing works

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.

Maude, S., Teachey, D., Porter, D., & Grupp, S. (2015) · Blood · doi:10.1182/blood-2014-12-580068 · Cited by 677 · see citing works

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

Ruella, M., Xu, J., Barrett, D. M., Fraietta, J. A., Reich, T. J., Ambrose, D. E., Klichinsky, M., Shestova, O., Patel, P. R., Kulikovskaya, I., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0201-9 · Cited by 659 · see citing works

GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts

Sterner, R. M., Sakemura, R. L., Cox, M. J., Yang, N., Khadka, R. H., Forsman, C. L., Hansen, M. J., Jin, F., Ayasoufi, K., Hefazi, M., et al. (2018) · Blood · doi:10.1182/blood-2018-10-881722 · Cited by 632 · see citing works

A novel chimeric antigen receptor containing a JAK–STAT signaling domain mediates superior antitumor effects

Kagoya, Y., Tanaka, S., Guo, T., Anczurowski, M., Wang, C.-H., Saso, K., Butler, M. O., Minden, M. D., & Hirano, N. (2018) · Nature Medicine · doi:10.1038/nm.4478 · Cited by 624 · see citing works

T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells

Zah, E., Lin, M.-Y., Silva-Benedict, A., Jensen, M. C., & Chen, Y. Y. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0231 · Cited by 609 · see citing works

The urgent need to recover MHC class I in cancers for effective immunotherapy

Garrido, F., Aptsiauri, N., Doorduijn, E. M., Garcia Lora, A. M., & van Hall, T. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.12.007 · Cited by 585 · see citing works

Regulatory mechanisms in T cell receptor signalling

Gaud, G., Lesourne, R., & Love, P. E. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0020-8 · Cited by 531 · see citing works

Programming self-organizing multicellular structures with synthetic cell-cell signaling

Toda, S., Blauch, L. R., Tang, S. K. Y., Morsut, L., & Lim, W. A. (2018) · Science · doi:10.1126/science.aat0271 · Cited by 470 · see citing works

Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer

Provasi, E., Genovese, P., Lombardo, A., Magnani, Z., Liu, P.-Q., Reik, A., Chu, V., Paschon, D. E., Zhang, L., Kuball, J., et al. (2012) · Nature Medicine · doi:10.1038/nm.2700 · Cited by 448 · see citing works

Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma

D’Angelo, S. P., Melchiori, L., Merchant, M. S., Bernstein, D. B., Glod, J. W., Kaplan, R. N., Grupp, S. A., Tap, W. D., Chagin, K., Binder, G. K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1417 · Cited by 432 · see citing works

A guide to manufacturing CAR T cell therapies

Vormittag, P., Gunn, R., Ghorashian, S., & Veraitch, F. S. (2018) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2018.01.025 · Cited by 389 · see citing works

Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes

Sockolosky, J. T., Trotta, E., Parisi, G., Picton, L. K., Su, L., Le, A., Chhabra, A., Silveria, S. L., George, B. M., King, I. C., et al. (2018) · Science · doi:10.1126/science.aar3246 · Cited by 383 · see citing works

Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes

Bentzen, A. K., Marquard, A. M., Lyngaa, R., Saini, S. K., Ramskov, S., Donia, M., Such, L., Furness, A. J. S., McGranahan, N., Rosenthal, R., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3662 · Cited by 332 · see citing works

Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity

Wang, D., Quiros, J., Mahuron, K., Pai, C.-C., Ranzani, V., Young, A., Silveria, S., Harwin, T., Abnousian, A., Pagani, M., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.050 · Cited by 318 · see citing works

Isolation of a Structural Mechanism for Uncoupling T Cell Receptor Signaling from Peptide-MHC Binding

Sibener, L. V., Fernandes, R. A., Kolawole, E. M., Carbone, C. B., Liu, F., McAffee, D. B., Birnbaum, M. E., Yang, X., Su, L. F., Yu, W., et al. (2018) · Cell · doi:10.1016/j.cell.2018.06.017 · Cited by 312 · see citing works

Dynamic Ligand Discrimination in the Notch Signaling Pathway

Nandagopal, N., Santat, L. A., LeBon, L., Sprinzak, D., Bronner-Fraser, M. E., & Elowitz, M. B. (2018) · Cell · doi:10.1016/j.cell.2018.01.002 · Cited by 311 · see citing works

Strength of PD-1 signaling differentially affects T-cell effector functions

Wei, F., Zhong, S., Ma, Z., Kong, H., Medvec, A. R., Ahmed, R., Freeman, G. J., Krogsgaard, M., & Riley, J. L. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305394110 · Cited by 306 · see citing works

Clonal Deletion Prunes but Does Not Eliminate Self-Specific αβ CD8+ T Lymphocytes

Yu, W., Jiang, N. J., Ebert, P. J. R., Kidd, B. A., Müller, S., Lund, P. J., Juang, J., Adachi, K., Tse, T., Birnbaum, M. E., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.05.001 · Cited by 301 · see citing works

Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II–Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3

Lu, Y., Parker, L. L., Lu, T., Zheng, Z., Toomey, M. A., White, D. E., Yao, X., Li, Y. F., Robbins, P. F., Feldman, S. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.5463 · Cited by 278 · see citing works

A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization

Drent, E., Themeli, M., Poels, R., de Jong-Korlaar, R., Yuan, H., de Bruijn, J. D., Martens, A. C., Zweegman, S., van de Donk, N. W. C. J., Groen, R. W. J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.04.024 · Cited by 276 · see citing works

Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes

Gee, M. H., Han, A. S., Lofgren, S., Beausang, J. F., Mendoza, J. L., Birnbaum, M. E., Bethune, M. T., Fischer, S., Yang, X., Gomez, R., et al. (2017) · Cell · doi:10.1016/j.cell.2017.11.043 · Cited by 273 · see citing works

In Vivo Antitumor Activity of Tumor-Infiltrating Lymphocytes Expanded in Recombinant Interleukin-2

Spiess, P. J., Yang, J. C.-H., & Rosenberg, S. A. (1987) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/79.5.1067 · Cited by 258 · see citing works

Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma

Dudley, M. E., Gross, C. A., Somerville, R. P. T., Hong, Y. K., Schaub, N. P., Rosati, S. F., White, D. E., Nathan, D., Restifo, N. P., Steinberg, S. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.6441 · Cited by 236 · see citing works

Targeting Alpha-Fetoprotein (AFP)–MHC Complex with CAR T-Cell Therapy for Liver Cancer

Liu, H., Xu, Y., Xiang, J., Li, L., Green, S., Yang, Z., Zimdahl, B., Lu, J., Cheng, N. N., Horan, L. H., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1203 · Cited by 233 · see citing works

The role of cytokines in T‐cell memory in health and disease

Raeber, M. E., Zurbuchen, Y., Impellizzieri, D., & Boyman, O. (2018) · Immunological Reviews · doi:10.1111/imr.12644 · Cited by 226 · see citing works

T cells for viral infections after allogeneic hematopoietic stem cell transplant

Bollard, C. M., & Heslop, H. E. (2016) · Blood · doi:10.1182/blood-2016-01-628982 · Cited by 217 · see citing works

Molecular analysis of PRC2 recruitment to DNA in chromatin and its inhibition by RNA

Wang, X., Paucek, R. D., Gooding, A. R., Brown, Z. Z., Ge, E. J., Muir, T. W., & Cech, T. R. (2017) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3487 · Cited by 211 · see citing works

Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy

Yossef, R., Tran, E., Deniger, D. C., Gros, A., Pasetto, A., Parkhurst, M. R., Gartner, J. J., Prickett, T. D., Cafri, G., Robbins, P. F., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122467 · Cited by 209 · see citing works

Strength of TCR–Peptide/MHC Interactions and In Vivo T Cell Responses

Corse, E., Gottschalk, R. A., & Allison, J. P. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003650 · Cited by 206 · see citing works

Antitumor effects of HSV-TK–engineered donor lymphocytes after allogeneic stem-cell transplantation

Ciceri, F., Bonini, C., Marktel, S., et al. (2007) · Blood · doi:10.1182/blood-2006-05-023416 · Cited by 172 · see citing works

Direct single molecule measurement of TCR triggering by agonist pMHC in living primary T cells

O’Donoghue, G. P., Pielak, R. M., Smoligovets, A. A., Lin, J. J., & Groves, J. T. (2013) · eLife · doi:10.7554/elife.00778 · Cited by 166 · see citing works

Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma

Quintarelli, C., Orlando, D., Boffa, I., Guercio, M., Polito, V. A., Petretto, A., Lavarello, C., Sinibaldi, M., Weber, G., Bufalo, F. D., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1433518 · Cited by 163 · see citing works

Landscape of Tumor Antigens in T Cell Immunotherapy

Ilyas, S., & Yang, J. C. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1501657 · Cited by 162 · see citing works

A TCR Targeting the HLA-A*0201–Restricted Epitope of MAGE-A3 Recognizes Multiple Epitopes of the MAGE-A Antigen Superfamily in Several Types of Cancer

Chinnasamy, N., Wargo, J. A., Yu, Z., Rao, M., Frankel, T. L., Riley, J. P., Hong, J. J., Parkhurst, M. R., Feldman, S. A., Schrump, D. S., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001775 · Cited by 161 · see citing works

T cell antigen discovery via trogocytosis

Li, G., Bethune, M. T., Wong, S. K., Joglekar, A. V., Leonard, M. T., Wang, J. K., Kim, J. T., Cheng, D., Peng, S., Zaretsky, J. M., et al. (2019) · Nature Methods · doi:10.1038/s41592-018-0305-7 · Cited by 161 · see citing works

T cell antigen discovery via signaling and antigen-presenting bifunctional receptors

Joglekar, A. V., Leonard, M. T., Jeppson, J. D., Swift, M., Li, G., Wong, S. K., Peng, S., Zaretsky, J. M., Heath, J. R., Ribas, A., et al. (2019) · Nature Methods · doi:10.1038/s41592-018-0304-8 · Cited by 151 · see citing works

Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer

Lee, J. K., Bangayan, N. J., Chai, T., Smith, B. A., Pariva, T. E., Yun, S., Vashisht, A. A., Zhang, Q., Park, J. W., Corey, E., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802354115 · Cited by 148 · see citing works

A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release

Xu, Y., Yang, Z., Horan, L. H., Zhang, P., Liu, L., Zimdahl, B., Green, S., Lu, J., Morales, J. F., Barrett, D. M., et al. (2018) · Cell Discovery · doi:10.1038/s41421-018-0066-6 · Cited by 122 · see citing works

Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy

Raman, M. C. C., Rizkallah, P. J., Simmons, R., et al. (2016) · Scientific Reports · doi:10.1038/srep18851 · Cited by 109 · see citing works

Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination

Akahori, Y., Wang, L., Yoneyama, M., Seo, N., Okumura, S., Miyahara, Y., Amaishi, Y., Okamoto, S., Mineno, J., Ikeda, H., et al. (2018) · Blood · doi:10.1182/blood-2017-08-802926 · Cited by 109 · see citing works

Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma

Yu, H., Sotillo, E., Harrington, C. T., Wertheim, G. B. W., Paessler, M. E., Maude, S. L., Rheingold, S. R., Grupp, S. A., Thomas‐Tikhonenko, A., & Pillai, V. (2016) · American Journal of Hematology · doi:10.1002/ajh.24594 · Cited by 94 · see citing works

Personalized T cell-mediated cancer immunotherapy: progress and challenges

Bethune, M. T., & Joglekar, A. V. (2017) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2017.03.024 · Cited by 90 · see citing works

Adoptive T‐cell therapy: adverse events and safety switches

Tey, S. (2014) · Clinical & Translational Immunology · doi:10.1038/cti.2014.11 · Cited by 86 · see citing works

Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor–Engineered T Cells for Ovarian Cancer

Matsuda, T., Leisegang, M., Park, J.-H., Ren, L., Kato, T., Ikeda, Y., Harada, M., Kiyotani, K., Lengyel, E. R., Fleming, G. F., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0142 · Cited by 80 · see citing works

Affinity and dose of TCR engagement yield proportional enhancer and gene activity in CD4+ T cells

Allison, K. A., Sajti, E., Collier, J. G., Gosselin, D., Troutman, T. D., Stone, E. L., Hedrick, S. Μ., & Glass, C. K. (2016) · eLife · doi:10.7554/elife.10134 · Cited by 74 · see citing works

Isolation and characterization of NY-ESO-1–specific T cell receptors restricted on various MHC molecules

Bethune, M. T., Li, X., Yu, J., McLaughlin, J., Cheng, D., Mathis, C., Moreno, B. H., Woods, K., Knights, A. J., García-Díaz, Á., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1810653115 · Cited by 72 · see citing works

Lower Affinity T Cells are Critical Components and Active Participants of the Immune Response

Martinez, R. J., & Evavold, B. D. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00468 · Cited by 71 · see citing works

Domain-swapped T cell receptors improve the safety of TCR gene therapy

Bethune, M. T., Gee, M. H., Bunse, M., Lee, M. S., Gschweng, E. H., Pagadala, M. S., Zhou, J., Cheng, D., Heath, J. R., Kohn, D. B., et al. (2016) · eLife · doi:10.7554/elife.19095 · Cited by 69 · see citing works

Early T cell receptor signals globally modulate ligand:receptor affinities during antigen discrimination

Pielak, R. M., O’Donoghue, G. P., Lin, J. J., Alfieri, K. N., Fay, N. C., Low-Nam, S. T., & Groves, J. T. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1613140114 · Cited by 69 · see citing works

RNAi-mediated TCR Knockdown Prevents Autoimmunity in Mice Caused by Mixed TCR Dimers Following TCR Gene Transfer

Bunse, M., Bendle, G. M., Linnemann, C., Bies, L., Schulz, S., Schumacher, T. N., & Uckert, W. (2014) · Molecular Therapy · doi:10.1038/mt.2014.142 · Cited by 67 · see citing works

Early Clinical Experience of CD19 x CD22 Dual Specific CAR T Cells for Enhanced Anti-Leukemic Targeting of Acute Lymphoblastic Leukemia

Gardner, R. A., Annesley, C., Finney, O. C., et al. (2018) · Blood · doi:10.1182/blood-2018-99-113126 · Cited by 65 · see citing works

The Serial Engagement Model 17 Years After: From TCR Triggering to Immunotherapy

Valitutti, S. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00272 · Cited by 57 · see citing works

Functionally Impaired HIV-Specific CD8 T Cells Show High Affinity TCR-Ligand Interactions

Ueno, T., Tomiyama, H., Fujiwara, M., Oka, S., & Takiguchi, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.9.5451 · Cited by 52 · see citing works

Catch Bonds at T Cell Interfaces: Impact of Surface Reorganization and Membrane Fluctuations

Pullen, R. H., & Abel, S. M. (2017) · Biophysical Journal · doi:10.1016/j.bpj.2017.05.023 · Cited by 33 · see citing works

Small molecule drugs with immunomodulatory effects in cancer

Murphy, A. G., & Zheng, L. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1057363 · Cited by 32 · see citing works

Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell Chronic Lymphocytic Leukemia and Solid Malignancies

Sandri, S., Bobisse, S., Moxley, K. M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2318 · Cited by 31 · see citing works

Novel CD19/CD22 Bicistronic Chimeric Antigen Receptors Outperform Single or Bivalent Cars in Eradicating CD19+CD22+, CD19-, and CD22- Pre-B Leukemia

Qin, H., Nguyen, S. M., Ramakrishna, S., Tarun, S., Yang, L., Verdini, N. P., Haso, W. M., & Fry, T. J. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.810.810 · Cited by 31 · see citing works

SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas.

Burgess, M. A., Crowley, J. J., Reinke, D. K., Riedel, R. F., George, S., Movva, S., Tine, B. A. V., Davis, L. E., Schuetze, S. M., Hu, J. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.tps10578 · Cited by 17 · see citing works

Immune Checkpoint Inhibitors in Cancer Therapy

Shiravand, Y., Khodadadi, F., Kashani, S. M. A., Hosseini-Fard, S. R., Hosseini, S., Sadeghirad, H., Ladwa, R., O’Byrne, K., & Kulasinghe, A. (2022) · Current Oncology · doi:10.3390/curroncol29050247 · Cited by 1,353 · see citing works

Transdiagnostic clinical staging in youth mental health: a first international consensus statement

Shah, J. L., Scott, J., McGorry, P. D., Cross, S. P. M., Keshavan, M. S., Nelson, B., Wood, S. J., Marwaha, S., Yung, A. R., Scott, E. M., et al. (2020) · World Psychiatry · doi:10.1002/wps.20745 · Cited by 291 · see citing works

Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression

Napolitano, S., Matrone, N., Muddassir, A. L., Martini, G., Sorokin, A., De Falco, V., Giunta, E. F., Ciardiello, D., Martinelli, E., Belli, V., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1497-0 · Cited by 40 · see citing works

Current status and problems of chimeric antigen receptor T cell immunotherapy in treatment of hematological malignancies

Yulin, X., Yongxian, H., Xiangjun, C., et al. (2020) · Guoji shuxue ji xueyexue zazhi · doi:10.3760/cma.j.issn.1673-419x.2020.01.001

The present situation and prospect of CAR-T cellular immunotherapy

Wang, B., Li, C., & Yang, Y. (2020) · Int J Immunol · doi:10.3760/cma.j.issn.1673-4394.2020.01.018

CAR-T Immunotherapy to Beat Solid Tumors: From Challenges to Improvements

Li, C., Liu, Z., & Zhou, Y. (2022) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v8i.1110 · Cited by 3 · see citing works

Universal chimeric antigen receptor T cell therapy — The future of cell therapy: A review providing clinical evidence

Sun, W., Jiang, Z., Jiang, W. G., & Yang, R. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100638 · Cited by 17 · see citing works

OPPORTUNITIES AND CHALLENGES FOR CAR T-CELL THERAPY IN CANCER

Soundararajan, S. (2022) · Cambridge Medicine Journal · doi:10.7244/cmj.2022.02.001